TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:35
Achilles Therapeutics plc ( ACHL ) https://www.achillestx.com
0.83USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
ACHL
3.79%
SPY
30.72%
ACHL
0.00%
SPY
112.82%
ACHL
0.00%
SPY
201.04%
ACHL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
34.22
-105.92
0.15
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.46
0.00
0.22
-188.93
0.00
1.38
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-29.39
-29.91
0.00
Other Earnings and Cash Flow Stats:
Achilles Therapeutics plc ( ACHL ) Net Income TTM ($MM) is -70.72
Achilles Therapeutics plc ( ACHL ) Operating Income TTM ($MM) is -76.52
Achilles Therapeutics plc ( ACHL ) Owners' Earnings Annual ($MM) is 0.00
Achilles Therapeutics plc ( ACHL ) Current Price to Owners' Earnings ratio is 0.00
Achilles Therapeutics plc ( ACHL ) EBITDA TTM ($MM) is -75.15
Achilles Therapeutics plc ( ACHL ) EBITDA Margin is 0.00%
Capital Allocation:
Achilles Therapeutics plc ( ACHL ) has paid 0.00 dividends per share and bought back -0.753158 million shares in the past 12 months
Achilles Therapeutics plc ( ACHL ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Achilles Therapeutics plc ( ACHL ) Interest-bearing Debt ($MM) as of last quarter is 0
Achilles Therapeutics plc ( ACHL ) Annual Working Capital Investments ($MM) are -16
Achilles Therapeutics plc ( ACHL ) Book Value ($MM) as of last quarter is 153
Achilles Therapeutics plc ( ACHL ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Achilles Therapeutics plc ( ACHL ) has 140 million in cash on hand as of last quarter
Achilles Therapeutics plc ( ACHL ) has 18 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Achilles Therapeutics plc ( ACHL ) has 40 common shares outstanding as of last quarter
Achilles Therapeutics plc ( ACHL ) has 0 million USD of preferred stock value
Academic Scores:
Achilles Therapeutics plc ( ACHL ) Altman Z-Score is -1.53 as of last quarter
Achilles Therapeutics plc ( ACHL ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Achilles Therapeutics plc ( ACHL ) largest shareholder is Morgan Stanley - Brokerage Accounts owning 72753 shares at 0.06 ($MM) value
(an insider) shares of Achilles Therapeutics plc ( ACHL ) for the amount of $ on
5.75% of Achilles Therapeutics plc ( ACHL ) is held by insiders, and 54.17% is held by institutions
Achilles Therapeutics plc ( ACHL ) went public on 2021-03-31
Other Achilles Therapeutics plc ( ACHL ) financial metrics:
FCF:-66.19
Unlevered Free Cash Flow:0.00
EPS:-1.67
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-43.48
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Achilles Therapeutics plc ( ACHL ) :
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.